Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
European Institute of Oncology
Age
18–70
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients with breast cancer histologically proven \> 2 cm, ER and PgR \<20% or Any ER and PgR absent (T2,T3 N0-2, M0)
No treatment with previous chemotherapy/hormonotherapy
Performance status 0-2 (ECOG scale, Appendix 2)
Measurable or evaluable lesions
Age between 18-70 years
No significant intercurrent illness such as diabetes, cardiovascular, renal or neurologic impairments
Absence of psychiatric illness
WBC \> 4,000/mm3; PLTS \> 100,000/mm3
AST, ALT, LDH, gamma-GT \< 2.5 x upper limit of normal and bilirubin \< 3 mg/100 ml
Informed consent obtained
Pregnancy test (in fertile women). An effective contraceptive method must be utilized by fertile women.
Baseline examinations (chest X ray, CT scan, ECG etc) performed within one month prior initiation to therapy
You may not be if
Uncontrolled infection and metabolite disease
Distant metastases
Active peripheric and/or central neurological disease
Active cardiac disease defined as CHF (NYHA III-IV) significant arrhytmias, bilateral bundle branch block or recent (less than 3 months) history of myocardial infarction
History of second malignancy (exception in situ carcinoma of the uterine cervix and basal or squamous cell carcinoma of the skin)
Clareo Health | Perioperative Chemotherapy After Primary Chemotherapy for Locally Advanced Breast Cancer
